FDA Panel Says Celebrex Should Stay

Feb. 18, 2005 - Celebrex should remain on the U.S. market despite evidence of its link to heart attacks and strokes in patients who take higher doses, an expert FDA panel said.

Experts advising the agency on the future direction of Cox-2 pain drugs, including Vioxx, Celebrex, and Bextra, voted 31 to 1 to recommend that the drug stay on the market. But the panel has not yet addressed concerns that warnings or restrictions may be required to prevent patients from taking higher doses of the drug.

http://my.webmd.com/content/Article/101/105995.htm?printing=true